Table 2

Frequency of known-reactive TCR clones in pre-REP and post-REP CD8+TIL^TP populations. Pre-REP frequencies taken from transcriptomic analysis of bulk TIL (n.d., not detected, <0.001%). Post-REP TIL n/a for sample 4382

Patient	TCR	CDR3b	TCR reactivity	Pre-REP frequency (% of CD3+)	Pre-REP enrichment (% of TP)	Post-REP frequency (% by CDR3b seq)
4323
	1	CATSGTGHSYEQYF	PPP2R1A	3.77	24.29	0.002
	2	CATSATGRSYEQYF	PPP2R1A	2.77	24.29	0.05
	3	CATSDTGRPYEQYF	PPP2R1A	3.43	18.57	1.1
	4	CASSPRVPNTEAFF	HIATL1	8.31	10.00	n.d.
	6	CASSQLTGAETQYF	PPP2R1A	0.11	2.86	n.d.
	9	CASSLDADGRSRETQYF	HIATL1	0.44	1.43	n.d.
	10	CSAATWAINQPQHF	PPP2R1A	0.33	1.43	n.d.
	(11)	CATSDTGKPYEQYF	PPP2R1A	0.11	–	2.3
	(12)	CATSDTGLPYEQYF	PPP2R1A	0.11	–	0.002
			Total known-reactive	19.38	82.86	3.45
4400
	2	CASSQDPGARDYGYTF	PDX tumor	1.48	3.39	n.d.
	3	CAWSRVRPNEQFF	PDX tumor	0.68	3.39	n.d.
	5	CASSELAGGNYNEQFF	PDX tumor	1.48	1.69	n.d.
	6	CASSLLATGNFNEQFF	PDX tumor	1.26	1.69	n.d.
	8	CASSFPASGGAVDNEQFF	PDX tumor	0.80	1.69	0.003
	(15)	CASTTSPGPEYGYTF	PDX tumor	0.68	–	0.01
			Total known-reactive	6.39	13.73	0.01
4385
	10	CASSMMNTEAFF	TMG6	0.08	–	1.30
			Total known-reactive	0.08	–	1.30
4317
	2	CASSIWATNTGELFF	AURKAIP1	3.11	17.65	3.45
	5	CASNSGGPTVEQYF	PIK3CA	1.14	3.92	1.67
	9	CASSAGAEQYF	PIK3CA	1.90	1.96	1.94
	10	CSVVLASGDEEEQYF	AURKAIP1	0.15	1.96	n.d.
	11	CSVEDGGRDTGELFF	AURKAIP1	0.08	1.96	n.d.
	(12)	CASSPGGFEAFF	PIK3CA	1.14	–	2.22
			Total known-reactive	7.51	27.45	9.27
4382
	2	CASSEAGASNYGYTF	SMARCA4	0.82	11.63	n/a
	4	CASSQSTGALETQYF	SMARCA4	0.41	9.30	n/a
			Total known-reactive	1.23	20.93	n/a

FACS, fluorescence-associated cell sorting; PDX, patient-derived xenograft; REP, rapid expansion protocol; TIL, tumor-infiltrating lymphocytes; TMG, tandem minigene .